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T
he most commonly used LC-MS based quantitative phos-
phoproteomics experiments are currently based on the
incorporation of stable isotope labels through stable-isotope
labeling by amino acids in cell culture (SILAC), proteolytic
digestion in the presence of
18O, or covalent peptide modiﬁca-
tions with isobaric tags for relative and absolute quantiﬁcation
(iTRAQ) reagents (reviewed in refs 1 3). Although SILAC is
very powerful for studies in transformed cell lines, analysis of
primary cells, tissues or biological ﬂuids using this method
requires SILAC-labeled animals, which is expensive and has only
be implemented in rodent, ﬂy, and newt models.
4 6 In addition,
a maximum of two or three unique experimental conditions may
be directly compared using
18O or SILAC labeling strategies,
respectively, limiting the complexity of the experimental design
which can be employed. The use of iTRAQ or TMT (Tandem
Mass Tag) labeling addresses some of these limitations by
covalently labeling peptides post-digestion from up to eight
diﬀerent experimental conditions, making the approach amen-
able to studying tissue or biological ﬂuids including nonpooled
biological replicates.
7 Those strategies, however, may introduce
additional quantitative variationfrom thelabelingprocedureand
maybecostprohibitivewhenworkingwithsamples(e.g.,tissues)
with relatively low levels of protein phosphorylation.
8 Impor-
tantly,quantitativeinformationfromiTRAQ/TMTexperiments
is only gained from precursor ions which were selected for MS/
MSfragmentationandprecludes theabilitytoperformfollow-up
experiments aimed at further interrogating qualitatively uniden-
tiﬁed, but statistically signiﬁcant, signals.
1
As an alternative to stable isotope labeling approaches several
label-free quantitation strategies, such as measuring area-under-
the-curve (AUC) intensities of peptide precursor ions following
accurate-mass and retention time alignment of raw LC-MS data,
have been described in the literature.
9 11 In addition to experi-
mentalcompatibilitywithtissueorbiologicalﬂuids,thisapproach
aﬀordsthecapabilityofmakingquantitativemeasurementsacross a
large number of biological samples without the requirement of
pooling. Although label-free approaches allow for ﬂexible experi-
mental designs, they are often associated with rigorous analytical
and informatic requirements, including: attention to reproduci-
bility of sample preparation and chromatographic separations;
automationofmultipleLC-MSﬁlealignment;andautomationof
precursoriondetectionandquantitation.
1,2Anadditionalsource
of possible variation in any label-free quantitative phosphoryla-
tion study is phosphopeptide enrichment prior to LC-MS
analysis, as each sample must be enriched independently.
Collectively, these challenges have limited the number of
globallabel-freequantitativephosphoproteomicsdescriptions
in the literature.
12 18
Herewedescribealabel-freequantitativephosphoproteomics
workﬂow which addresses the above concerns and applied it
to study the eﬀects of a morpholino induced knock-down of
G protein-coupled receptor kinase 5 (GRK5) in Danio rerio
Received: January 28, 2011
Accepted: April 14, 2011
ABSTRACT: Protein phosphorylation is a critical regulator of signaling in
nearly all eukaryotic cellular pathways and dysregulated phosphorylation has
been implicated in an array of diseases. The majority of MS-based quantitative
phosphorylation studies are currently performed from transformed cell lines
because of the ability to generate large amounts of starting material with
incorporated isotopically labeled amino acids during cell culture. Here we
describe a general label-free quantitative phosphoproteomic strategy capable of
directly analyzing relatively small amounts of virtually any biological matrix,
including human tissue and biological ﬂuids. The strategy utilizes a TiO2 enrichment protocol in which the selectivity and recovery
of phosphopeptides were optimized by assessing a twenty-point condition matrix of binding modiﬁer concentrations and peptide-
to-resin capacity ratios. The quantitative reproducibility of the TiO2 enrichment was determined to be 16% RSD through replicate
enrichments of a wild-type Danio rerio (zebraﬁsh) lysate. Measured phosphopeptide fold-changes from alpha-casein spiked into
wild-typezebraﬁshlysatebackgroundswerewithin5%ofthetheoreticalvalue.Applicationtoamorpholinoinducedknock-downof
G protein-coupled receptor kinase 5 (GRK5) in zebraﬁsh embryos resulted in the quantitation of 719 phosphorylated peptides
corresponding to 449 phosphorylated proteins from 200 μg of zebraﬁsh embryo lysates.3759 dx.doi.org/10.1021/ac200213b |Anal. Chem. 2011, 83, 3758–3764
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(zebraﬁsh) embryos. To enhance the quantitative robustness
of the label-free phosphoproteomic analysis, an optimized
TiO2 enrichment strategy was ﬁrst developed using wild-type
zebraﬁsh embryo lysates enriched under a matrix of twenty
unique conditions. The goal of this TiO2 enrichment optimi-
zation was to reduce the percent of nonphosphorylated peptide
interference, maintain high recovery of phosphopeptides and
avoid bias of the enrichment for any particular subset of phos-
phorylated species.
’MATERIALS AND METHODS
Chemicals and Materials. MassPrep Enhancer and Rapigest
SF acid-cleavable surfactant were purchased from Waters
Corporation (Milford, MA). TiO2 resin was purchased from
Protea Biosciences (Morgantown, WV) as part of the TiO2
SpinTip Sample Prep Kit (product number SP-154 24).
Approximately193mgoflooseTiO2resinwithamanufacturer
reported binding capacity of 25.9 μg/mg resin was combined
from five purchased columns. Danio rerio (zebrafish) husban-
dry and morpholino induced knock-down of GRK5 is de-
scribed in Supporting Information. All other regents were
purchased at the highest available purity from commercial
sources.
ProteinExtractionandDigestion.Dechorionatedanddeyolked
embryos were lysed in 50 mM ammonium bicarbonate (pH 8.0)
containing0.4%RapiGestSFandphosphataseinhibitors(1mMKF,
1m MN a V O 4) by three 10s pulses of burst sonication intermitted
bycoolingonicefor30s.Sampleswerecentrifugedandsupernatants
were reduced with 5 mM DTT at 60 C for 20 min and alkylated
with 10 mM iodoacetamide at room temperature in the dark for
45 min. Trypsin was added to final ratio (w/w) of 1:50 enzyme-to-
protein and digestion was performed at 37 C for 18 h. All samples
were spiked with trypsin digested R-casein at 30 fmol R-casein per
1 μgo fz e b r a f i s hl y s a t ea n df r o z e na t 80 C until phosphopeptide
enrichment was performed.
Phosphopeptide Enrichment. TiO2 spin columns were
packed using 200 μL gel-loading pipet tips with a 1 mm   1
mm15 45umX-4900UHMWPorex(Fairburn,GA)plug.The
resin bed was compressed three times by adding 10 column
volumes of 20% acetonitrile, 5% NH4OH (pH 10.5) followed by
centrifugation at 200 rcf for 1 min. The column was then re-
equilibrated by adding 200 μL of 80% acetonitrile, 1% TFA
(pH 2.5) (wash buffer A) followed by centrifugation at 200 rcf
for 1 min.
For TiO2 enrichment condition optimization, ﬁve aliquots
each of 20, 100, 200, or 400 μg wild-type zebraﬁsh lysate were
brought to dryness using vacuum centrifugation and resuspended
in wash buﬀer A with either 0, 50, 100, 200, or 300 mg/mL
MassPrep Enhancer. Three additional aliquots of 350 μg wild-
typezebraﬁshlysatesinwashbuﬀerAand200mg/mLMassPrep
Enhancerwerepreparedforreproducibilitystudiesandtwoaddi-
tional 1000 μg aliquots spiked with 25 fmol/μg or 75 fmol/μg
bovine alpha-casein in wash buﬀer A and 200 mg/mL MassPrep
Enhancer were prepared for quantitative spiking experiments.
Samples were loadedinto a TiO2 spin column containing 7.7 mg
or 35.8 mg of resin and centrifuged at 100 rcf for 2 min for
enrichmentconditionandreproducibilityexperimentsorspiking
experiments, respectively. The unbound ﬂow through was re-
applied to the top of the column and centrifuged a second time.
BoundpeptideswerewashedoncewithwashbuﬀerAcontaining
the same amount of MassPrep Enhancer as in the sample and
then twice with wash buﬀer A alone. Remaining peptides were
eluted twice with 100 μL 20% acetonitrile, 5% NH4OH
(pH 10.5), acidiﬁed to pH 3.5 with neat formic acid and brought
to dryness using vacuum centrifugation.
For GRK5 knock-down experiments, two separate 200 μg
aliquots of lysate from each treatment group was resuspended in
washbuﬀerAwith100mg/mLMassPrep Enhancerwereapplied
to a TiO2 spin column containing 3.85 mg of TiO2 resin and
brought through the same phosphopeptide enrichment protocol
as described above.
Nanoflow Liquid Chromatography Electrospray Ioniza-
tion Tandem Mass Spectrometry (LC-MS/MS). Samples were
resuspended in 20 μL 2% acetonitrile, 0.1% formic acid, 50 mM
citric acid (pH 3.0) and injected onto a Waters NanoAquity
UPLC equipped with a 1.7 μm BEH130 C18 75 μmi . d .  250 mm
reversed-phase column. The mobile phase consisted of (A) 0.1%
formic acid in water and (B) 0.1% formic acid in acetonitrile.
Following a 4 μL injection, peptides were trapped for 5 min on a
5μmSymmetryC18180μmi.d. 20mmcolumnat20μL/min
in 99.9% A. The analytical column was then switched in-line
and the mobile phase was held for 5 min at 5% B before apply-
ing a linear elution gradient of 5% B to 40% B over 90 min at
300 nL/min.
MS data for all TiO2 enrichment optimization and evaluation
experiments were acquired on a Waters Synapt HDMS G1 mass
spectrometerusingtwodiﬀerentacquisitionstrategies.Forquali-
tative only acquisitions, the instrument was operated in data-
dependent acquisition (DDA) mode with a precursor MS scan
from m/z 50 to 1990, followed by 3 MS/MS product ion scans
from m/z 50 to 1990 with a charge-state dependent CID energy
setting. For qualitative/quantitative acquisitions, the instrument
was operatedinadata-independent analysis(DIA) high-energy/
low-energy alternative scanning (MS
E) mode with a 0.9 s low-
energy precursor MS scan from m/z 50 1990 followed by a
high-energy MS scan from m/z 50 1990 with a CID energy set
to ramp from 15 v to 40 v. The duty cycle of this acquisition was
approximately 2 s and allowed a minimum of 10 low-energy MS
spectra to be acquired across a 20 s chromatographic peak. This
improvementindutycycleinherentinDIAcomparedwithDDA
signiﬁcantly improves the quantitative rigor and reproducibility
oftheanalysis.Toincreasecoverageoflowerabundantprecursor
ions, a 120 s dynamic exclusion list was employed for all DDA
acquisitions. For both acquisitions, a separate LC channel with
200 fmol/μL Glu-1-Fibrinopeptide in 50% acetonitrile/0.1%
formic acid ﬂowing at 500 nL/min was referenced every 30 s
through a nano lock-spray interface.
MS data from GRK5 knock-down experiments were acquired
on a Thermo LTQ-Orbitrap XL mass spectrometer using two
diﬀerent acquisition strategies For all acquisitions, the instru-
ment was set to acquire a precursor MS scan from m/z 400 
2000 with r = 60,000 at m/z 400 and a target AGC setting of 1e6
ions.MS/MSspectraforthetop10precursorionswereacquired
intheLTQforqualitativeonlyacquisitionsandthetop5ortop2
precursor ions were acquired in the LTQ or FT, respectively, for
qualitative/quantitative acquisitions. For all experiments, frag-
mentationoccurredintheLTQlineariontrapwithaCIDenergy
setting of 35% and a dynamic exclusion of 60 s for previously
fragmented precursor ions.
QualitativePeptideIdentification.DTAfiles from each LC-
MS analysis were submitted to Mascot (Matrix Science, Boston,
MA) searches against a forward-reverse NCBI Danio rerio protein
databaseappendedwithbovineR,β,andγcaseinproteinentries.3760 dx.doi.org/10.1021/ac200213b |Anal. Chem. 2011, 83, 3758–3764
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Search tolerances of 20 ppm precursor and either 0.04 or 0.8
Da product ions were applied for Synapt HDMS data files or
LTQ-Orbitrap files, respectively. Spectra were searched using
trypsin specificity with up to two missed cleavages. Carbami-
domethylation (þ57.0214 Da on C)was a fixed modification,
whereas oxidation (þ15.9949 Da on M)and phosphorylation
(þ79.9663 Da on STY)were considered as variable modifica-
tions. Peptide FDR was determined by adjusting the Mascot
peptide ion score threshold to allow a 1% occurrence of
peptides from reverse protein entries. All qualitative data are
available at ProteomeCommons.org as described in Support-
ing Information.
’RESULTS AND DISCUSSION
Label-Free Phosphopeptide Quantitation Workflow. Gen-
eral Label-Free Quantitation Strategy Using Rosetta Elucidator. A
generalizedoverviewoftheworkflowutilizedintheseexperiments
is illustrated in Figure 1. To assess TiO2 enrichment performance
and quantitative reproducibility, digested lysates were spiked with
30 fmol of bovine alpha-casein digest per 1 μgo fl y s a t ep r i o rt o
enrichment. Samples were then subjected to a single qualitative
only acquisition and three qualitative/quantitative acquisitions
intended to either maximize the number of qualitative identifica-
tions or provide a quantitatively accurate description of the
peptide’s chromatographic elution profile, respectively. Although
qualitative peptide identifications were generated from both types
modes of acquisitions, only peak areas from qualitative/quantita-
tive acquisitions were used for quantitative data interpretation.
Label-free quantitation and integration of qualitative peptide
identiﬁcations was performed using Rosetta Elucidator (v 3.3,
Rosetta Inpharmatics, Seattle, WA). Following chromatographic
retentiontimealignmentofallLC-MSdatawithinanexperiment
using the PeakTeller algorithm, quantitation of all detectable
features (an individual isotopomer within a precursor ion’sc h a r g e
state envelope) in the precursor MS spectra was performed by
measuring either peak area under curve (Synapt HDMS data) or
peak height (LTQ-Orbitrap data) measurements of the corres-
ponding extracted ion chromatograms.
19 Qualitative identiﬁcations
assignedtoaspeciﬁcfeaturewerealsoprojectedtofeaturesofthe
same retention time and m/z across all LC-MS analysis, regard-
lessifthepeptidewas qualitativelyidentiﬁedinthe other runs, in
a method analogous to the Smith et al. AMT approach.
10 Fold-
change values between WT and GRK5 knock-down treatment
groups were calculated on the peptide level from the averages of
the sum of all features associated with the precursor ion within a
biological replicate. To account for slight diﬀerences in total
peptide loading between injections, all of the features within an
LC-MS analysis were subjected to a robust mean normalization
of all of the feature intensities which excluded the highest and
lowest 10% of the signals.
Optimizing Global Phosphorylation Enrichment. Effects
of TiO2 Enrichment Condition on Global Peptide Composition. Of
critical importance to any quantitative label-free phosphopro-
teomics platform is establishing an effective and reproducible
TiO2 enrichment prior to LC-MS analysis, as each sample must
be enriched independently. Phosphopeptide enrichments are
known to be dependent on a number of factors including peptide-
to-resincapacityratios,
20,21pHofthesamplebuffer,
22,23andtheuse
of various buffer additives (such as 2,4-dihyroxybenzoic acid
(DHB))toreducebindingofnonphosphorylatedpeptides.
24 27
The influence of these variables was observed in a pilot phos-
phopeptide enrichment of 2 pmol of R-casein with a ProteaTip
TiO2 tip using the manufacturers supplied buffers versus a
generalizedbuffersystem(80%acetonitrile,50mg/mLmodifier,
1% TFA) previously described.
24 Although nine unique phos-
phorylated peptides were identified following both protocols, six
nonphosphorylated peptides were identified using the manufac-
turers protocol identified compared to only one nonphosphory-
lated peptide using the generalized buffer system protocol
identified (data not shown).
Although the eﬀects of varying resin capacity and buﬀer modiﬁes
have been individually described, the codependence of these
variables has not been investigated in detail. To maximize
enrichment speciﬁcity and yield of recovered phosphopeptides,
a matrix of twenty diﬀerent enrichment conditions varying in
peptide-to-resin capacity ratios and MassPrep Enhancer concen-
trations was generated. For each enrichment condition, digested
Figure1. Generaloverviewof(A)samplepreparationanddataacquisitionstrategyand(B)dataanalysisworkﬂowutilizedinthelabel-freequantitative
phosphoproteomic analysis of WT vs GRK5 knock-down zebraﬁsh embryos.3761 dx.doi.org/10.1021/ac200213b |Anal. Chem. 2011, 83, 3758–3764
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wild-type zebraﬁsh lysate was applied to a 200 μg binding capa-
city TiO2 spin column and an identical enrichment and elution
sequence was employed (see Materials and Methods). Samples
from each point in the matrix were subjected to the label-free
quantitative workﬂow described above on a Synapt HDMS. To
assess the composition of individual peptides or groups of
peptides as a function of enrichment condition, the intensities
of individual peptides or summed intensities of groups of peptides
wereplottedonathree-dimensionalsurfaceplotwithpeptide-to-
resin capacity ratio and MassPrep Enhancer concentration axis.
This strategy was preferred over total spectral counts as measur-
ingtheabundanceofeachpeptideacrossallconditionsallowsfor
a more accurate description of the eﬀectiveness of each enrich-
ment condition on a per peptide basis.
The inﬂuence of varying peptide-to-resin capacity ratios and
MassPrep Enhancer concentration on total phosphorylated and
nonphosphorylatedpeptideintensitiesareillustrated inFigure2.
Consistent with observations that DHB decreases nonphos-
phorylated peptide binding, addition of 50 or 100 mg/mL of
MassPrep Enhancer reduced the summed intensity of nonpho-
sphorylatedpeptidesby68%or82%atapeptide-to-resinratioof
1:1,respectively,withanegligiblereductionobservedwithhigher
MassPrep Enhancer concentrations (Figure 2A). Reductions in
the abundance of nonphosphorylated peptides up to 76% were
also observed by increasing the peptide-to-resin capacity ratio
from0.1:1to2:1intheabsenceofMassPrepEnhancer,evidently
due to the increased abundance of phosphorylated peptides in
the mixture out competing nonphosphorylated peptides for
TiO2 binding sites.
Although the most eﬀective reduction in the abundance of
nonphosphorylated peptides was obtained by simultaneously
increasing both MassPrep Enhancer and peptide-to-resin capa-
city ratios, these conditions did not provide the highest total
yield of phosphorylated peptides (Figure 2B). While it was not
surprising that increasing the peptide-to-resin capacity resulted
in higher abundances of phosphorylated peptides, it was ob-
served that the addition of 50 or 100 mg/mL of MassPrep
Enhancer reduced the summed intensity of phosphorylated
peptides by 7% or 25%, respectively, at a peptide-to-resin capacity
ratioof 2:1. Thisis an important consideration when performing
TiO2-based phosphopeptide enrichments from sample matrices
such as tissue which typically yield low amounts of total
phosphorylated peptides per wet weight of tissue, as not analyz-
ing a full column load (1 μg target amount per injection) will
reducethenumberofsignalswhichareidentiﬁedinthelabel-free
experiment.
To assess enrichment speciﬁcity, the summed intensity of the
phosphorylated peptides were calculated as a percentage of the
total summed peptide intensity (Figure 3). The global speciﬁcity
for all phosphopeptides varied from 6% at a peptide-to-resin
capacity ratios of 0.1:1 and 0 mg/mL MassPrep Enhancer up to
80% at a peptide-to-resin capacity ratios of 2:1 and 300 mg/mL
MassPrep Enhancer (Figure 3A). Generally, higher concentra-
tionsofMassPrepEnhancerincreasestheenrichmentspeciﬁcity,
however the gain in speciﬁcity with more than 100 mg/mL
MassPrep Enhancer was minimal for all peptide-to-resin ratios.
Surprisingly, an increase in global phosphopeptide enrichment
speciﬁcity by as much as 64% was observed by simply increasing
theratioofpeptide-to-resincapacityfrom0.1:1to2:1.MassPrep
Enhancer seems to have modest eﬀects on overall speciﬁcity at
highandlowPeptide-to-Resinratios (10% and 14%, respectively)
while having the greatest eﬀect at intermediate loading ratios
(40% improvement). These data suggest conditions of peptide-
to-resin ratios of 2:1 with 50 mg/mL to 200 mg/mL MassPrep
Enhancer provide optimal enrichment conditions to provide
relatively high speciﬁcity and absolute phosphopeptide intensity
(Supporting Information, Table S-1).
To investigate if these conditions resulted in a biased enrich-
ment of subsets of phosphorylated peptides, the enrichment
speciﬁcity of unique singly (n = 164) and unique multiply
phosphorylated (n = 41) peptides were plotted (Figure 3 B C).
The enrichment speciﬁcity distributions for these subsets of
phosphopeptides clearly indicated a diﬀerentiation in optimal
enrichment conditions for singly- and multiply phosphorylated
peptides, with higher MassPrep Enhancer concentrations and
peptide-to-resincapacityratiosfavoringtheenrichmentofmulti-
ply phosphorylated peptides. Even under conditions where
MassPrep Enhancer concentrations had a small eﬀect on overall
speciﬁcity (2:1 peptide-to-resin), it has a large apparent eﬀect on
the relative composition of singly and multiply phosphorylated
species. Example phosphorylated peptides from nuclear casein
kinase and cyclin-dependent kinase substrate-1 identiﬁed in its
singly- and doubly phosphorylated form (SSPKDEEEAE[pS]-
PAEDEEEDEVEK and S[pS]PKDEEEAE[pS]PAEDEEEDEVEK)
clearly demonstrates that the optimal enrichment condition for
the doubly phosphorylated version was shifted toward higher
amounts of MassPrep Enhancer (Supporting Information, Fig-
ureS-1). ThesedatasuggestthatsequentialTiO2enrichments at
diﬀerent enrichment conditions could be used to eﬀectively
select for distinct subpopulations of phosphorylated peptides
from a single sample without requiring a change of TiO2 column
hardware. Such a strategy may represent a viable fractionation
approach to increase phosphopeptide coverage. Although no
single enrichment condition was found to be optimal for both
singly- and multiply phosphorylated peptides, all proceeding
Figure 2. Three-dimensional surface plots of the summed areaunder-
curve extracted ion chromatograms intensities for all (A) unique
nonphosphorylated peptides (n = 665) or (B) unique phosphorylated
peptides (n = 205) from WT zebraﬁsh embryo lysates subjected to
twenty unique TiO2 enrichment conditions.3762 dx.doi.org/10.1021/ac200213b |Anal. Chem. 2011, 83, 3758–3764
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experiments utilized peptide-to-resin capacity ratios of 2:1 and
100 mg/mL MassPrep Enhancer which we found provided
excellent enrichment speciﬁcity for phosphopeptides (∼75%)
androbustquantitativereproducibility(SupportingInformation,
Table S-1).
Quantitative Reproducibility and Accuracy of TiO2 Enrich-
ment. Quantitative reproducibility of the TiO2 enrichment was
determined by subjecting three 350 μg aliquots of wild-type
zebrafishembryolysatetoenrichmentsusingdifferentTiO2spin
columns. Variation of phosphopeptide intensity values between
replicate injections (analytical variation) and between individual
TiO2enrichments (analyticalþ TiO2 enrichment variation) was
determined by generating coefficient of variation (% CV) distri-
butions of the quantitative values for all identified phosphory-
lated peptides (Figure 4A). Approximately 80% of the peptides
had an analytical variation below 20%, with median CVs of as
7.6%, 6.7%, and 6.6%. Variation across all three TiO2 enrich-
ments resulted in approximately 80% of the phosphorylated
peptideshavingCVslessthana33%withamedianCVof23.5%,
indicating that the variation from the TiO2 enrichment itself was
approximately 16%.
To determine if speciﬁc subsets of peptides were correlated
with higher variation between TiO2 enrichments, CV distribu-
tions were recalculated using nonphosphorylated peptides
(n = 88), singly phosphorylated peptides (n = 58), or multiply
phosphorylated peptides (n = 42) (Figure 4B). These distribu-
tions clearly indicate that enrichment variability is higher for
nonphosphorylated peptides (median CV of 44%) as compared
to singly- and multiply phosphorylated peptides (median CVs of
23.4% and 19.7%, respectively). Moreover, these reproducibility
metrics also showed a very weak correlation as a function of
phosphopeptideintensity,astheaverageCVofthephosphopep-
tides in the lowest quartile of intensity was 11.0%, and CVs for
the second, third, and fourth quartiles were 16%, 9.4%, and 8.7%
respectively. These results demonstrate that TiO2 enrichment
can be performed reproducibly and as such enables this portion
of the protocol to be compatible with downstream label-free
quantitation, however nonphosphorylated peptides which are
nonspeciﬁcally enriched should generally not be considered in
quantitative experiments.
The ability of the TiO2 enrichment to accurately measure a
change in phosphopeptide abundance was investigated by spik-
ing 1000 μg of wild-type zebraﬁsh lysate with 25 fmol or 75 fmol
ofpredigestedbovineR-caseinpeptideperμgoflysate(Table1).
Consistentwith the results from the analytical þ TiO2enrichment
variation experiment, the average measured fold-change across all
non-casein (background) phosphorylated peptides between the
two conditions was 0.95 with an average RSD of 23.8%. Measured
fold changes for three unique phosphorylated R-casein peptides
(onesinglyphosphorylatedpeptideswasidentiﬁedintwodiﬀerent
charge states) varied from 2.89 to 3.57, which an average fold-
change of 3.11 and an RSD of 10.2%. The measured fold-change
across all casein phosphopeptidestherefore deviated <5%from the
theoretical 3-fold measurement, which is well within the deter-
mined analytical þ TiO2 enrichment variability of this workﬂow.
Figure 3. Phosphorylated peptide TiO2 enrichment speciﬁcity across a twenty-point matrix of enrichment conditions. Speciﬁcity was determined by
calculating the percentage of the summed area-under-curve extracted ion chromatogram intensities for (A) all unique phosphopeptides (n = 205), (B)
phosphopeptides containing 1 phosphate (n=164), or(C) phosphopeptides containing morethan 1phosphate (n=41)as apart ofthesummed area-
under-curve extracted ion chromatogram intensities for all identiﬁed peptides (n = 871).
Figure 4. Analytical and TiO2 enrichment variation from three 350 ug
WT zebraﬁsh embryo lysates subjected to independent TiO2 enrich-
ments followed by triplicate LC-MS/MS analysis. (A) Coeﬃcient of
variation (CV%) distributions for all phosphorylated peptide extracted
ionchromatogramintensities(n=99)foreachsetofanalyticalreplicates
(average median CV 7.0%) or across all three TiO2 enrichments
(median CV 23.5%). (B) Coeﬃcient of variation distributions of non-
phosphorylated (n = 88, median CV 44.0%), singly phosphorylated
(n = 57, median CV 23.4%), and multiply phosphorylated (n = 42,
median CV 19.7%) peptide intensities across all three TiO2 enrichments.3763 dx.doi.org/10.1021/ac200213b |Anal. Chem. 2011, 83, 3758–3764
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Quantitative Analysis of GRK5 Knock-down Zebrafish. To
demonstrate the utility of the workflow on a more biologically
complex system, a differential analysis of wild-type zebrafish
embryos and those injected with a morpholino (MO) targeted
against the closest homologue of mammalian G-protein coupled
receptor kinase 5 (GRK5) was conducted. GRK5 is one of the
seven members of the family of G protein-coupled receptor
kinases,whichwereoriginallyidentifiedasthekinasesphosphor-
ylating and thus desensitizing G protein-coupled receptors.
28
Across all LC-MS analyses, 719 unique phosphorylated peptides
from449proteinswereidentifiedatapeptidefalsediscoveryrate
of 1.1%. The specificity of phosphopeptide enrichment varied
between 87.4% to 94.8%, with an average enrichment specificity of
90.2%. The median analytical variation of phosphopeptide intensity
valuesacrossallanalysiswas7.9%RSDandthemediananalyticalþ
TiO2 enrichment variation was 20.3% RSD for wild-type embryos
and 21.9% RSD for GRK5 knock-down embryos (Supporting
Information, Figure S-2). Seven unique casein phosphorylated
peptides (three singly phosphorylated, two doubly phosphorylated,
and two triply phosphorylated) spiked into each sample prior to
enrichmentyieldedanaverageanalyticalvariationsof5.1%RSDand
an average analytical þ TiO2 enrichment of 17.7% RSD variations
across all samples (Supporting Information, Table S-2).
Of the identiﬁed phosphorylated peptides, 60% contained a
singlephosphate,32%containedtwophosphates,and8%contained
three or more phosphates, consistent with the distributions pre-
dicted from the enrichment condition matrix (Supporting Informa-
tion, Figure S-3). Of the 719 unique phosphorylated peptides, 24
were down-regulated and 27 were up-regulated with a minimum
absolute fold-change of 2.0 and a p-value of less than 0.05 as a
function of GRK5 knock-down (Supporting Information, Table
S-3).Manualkinasemotifsearchesofphosphorylatedresiduesfrom
the up-regulated group of phosphopeptides revealed a preference
for serine residues neighbored by acidic residues (17 of the 27
contained the motif [pS/T]D/E) and indicate acidophilic serine/
threonine kinases such as casein kinases and GSK3 may become
activated in response to GRK5 knock-down (Supporting Informa-
tion,FigureS-3).Itremainstobetestedifthesespeciﬁcproteinsare
in fact direct targets of GRK5 or if the phosphorylation of these
residues is due to activation of other acidophilic kinases from
alternative signaling pathways.
’CONCLUSIONS
This work described a quantitatively robust label-free phos-
phoproteomic workﬂow capable of analyzing relatively small
amounts (100s of micrograms) of sample directly from any
biological matrix, including human tissue and biological ﬂuids.
Traditionally, label-free strategies have had limited utility in
global quantitative phosphoproteomics because of the require-
ment to prepare and enrich multiple samples independently. We
thereforefocusedonestablishingareproduciblesingle-stepTiO2
basedenrichmentstrategy aimed at reducingthe binding ofnon-
phosphorylatedpeptideswhilemaximizing the total signal inten-
sity of phosphorylated peptides. From this work we determined
that optimal conditions of 100 mg/mL MassPrep Enhancer and
2:1 peptide-to-resin binding capacity could provide excellent
enrichment speciﬁcity for phosphopeptides and robust quanti-
tative reproducibility. Interestingly, our results indicated that
even with the same TiO2 column, signiﬁcantly diﬀerent enrich-
mentspeciﬁcitiesbetween6%and80%couldbeobtainedsimply
by changing the initial loading buﬀers or total loading amounts.
One potential advantage of this could be in selecting for speciﬁc
subpopulations of phosphorylated peptides with a potential for
increaseddepthofphosphoproteomecoveragethroughreplicate
enrichments at diﬀerent conditions. Although the number of
qualitative identiﬁcations in the GRK5 knock-down study is lower
than many global phosphoproteomics reports, the samples were
not subjected to additional orthogonal fractionations reducing
the total analysis time to two hours per replicate. This is im-
portant factor when considering extrapolating the approach to
larger biological cohorts and multifaceted experimental designs
in which many samples would need to be analyzed in a realistic
timeline.
’ASSOCIATED CONTENT
b S Supporting Information. Additional material as described
inthetext.Thismateriali savailablefreeofchargeviatheInternetat
http://pubs.acs.org.
’AUTHOR INFORMATION
Corresponding Author
*E-mail: Arthur.Moseley@duke.edu. Fax: 919.668.7633.
Present Addresses
§Institute of Biochemistry and Molecular Biology, University of
Ulm, Germany.
’ACKNOWLEDGMENT
We thank Dr. Robert Lefkowitz and the Howard Hughes
Medical Institute for use of Thermo LTQ-Orbitrap XL mass
spectrometer. We thank Dr. Matthew Foster for manuscript
editing and helpful discussions. This work was funded through
internal funds from the Duke UniversitySchool of Medicine and
by Duke University’s CTSA grant 1 UL1 RR024128-01 from
NCRR/NIH. MP was supported by a Marie Curie Outgoing
International Fellowship of the European Commission.
’REFERENCES
(1) Tedford, N. C.; Hall, A. B.; Graham, J. R.; Murphy, C. E.;
Gordon, N. F.; Radding, J. A. Proteomics 2009, 9, 1469–1487.
(2) Nita-Lazar, A.; Saito-Benz, H.; White, F. M. Proteomics 2008,
8, 4433–4443.
(3) Schreiber, T. B.; Mausbacher, N.; Breitkopf, S. B.; Grundner-
Culemann, K.; Daub, H. Proteomics 2008, 8, 4416–4432.
Table 1. Accuracy of Quantitative Enrichment Assessed by
Spiking 1000 μg WT Zebraﬁsh Embryo Lysates with 25 fmol
Bovine r-Casein/μg Lysate or 75 fmol Bovine r-Casein/μg
Lysate and Subjecting to TiO2 Enrichment Followed by
Triplicate LC-MS/MS Analysis
a
peptide
intensity
25 fmol/ug
CV
%
intensity
75 fmol/ug
CV
%
fold
change
[VPQLEIVP NS*AEER]
2þ 54824 1.9 158448 1.7 2.9
[YKVPQLEIV PNS*AEER]
2þ 32659 16.5 116737 22.0 3.6
[YKVPQLEIV PNS*AEER]
3þ 10032 8.6 30623 13.6 3.1
[DIGS*ES*T EDQAMEDIK]
2þ 3514 3.6 10297 5.5 2.9
aAverage analytical coeﬃcient of variations (CV%) were 9.2% and
average measured fold increase across three unique phosphorylated
peptides (* = site of modiﬁcation) was 3.11 fold (R.S.D 10.2%).3764 dx.doi.org/10.1021/ac200213b |Anal. Chem. 2011, 83, 3758–3764
Analytical Chemistry ARTICLE
(4) Looso, M.; Borchardt, T.; Kruger, M.; Braun, T. Mol. Cell
Proteomics 2010, 9, 1157–1166.
(5) Sury, M. D.; Chen, J. X.; Selbach, M. Mol. Cell Proteomics 2010,
9, 2173–2183.
(6) Kruger, M.; Moser, M.; Ussar, S.; Thievessen, I.; Luber, C. A.;
Forner, F.; Schmidt, S.; Zanivan, S.; Fassler, R.; Mann, M. Cell 2008,
134, 353–364.
(7) Latterich, M.; Abramovitz, M.; Leyland-Jones, B. Eur. J. Cancer
2008, 44, 2737–2741.
(8) Lin,W.T.;Hung,W.N.;Yian,Y.H.;Wu,K.P.;Han,C.L.;Chen,
Y. R.; Chen, Y. J.; Sung, T. Y.; Hsu, W. L. J. Proteome Res. 2006, 5,
2328–2338.
(9) Lipton, M. S.; Pasa-Tolic, L.; Anderson, G. A.; Anderson, D. J.;
Auberry, D. L.; Battista, J. R.; Daly, M. J.; Fredrickson, J.; Hixson, K. K.;
Kostandarithes,H.;Masselon,C.;Markillie,L.M.;Moore,R.J.;Romine,
M.F.;Shen,Y.;Stritmatter,E.;Tolic,N.;Udseth,H.R.;Venkateswaran,
A.;Wong,K.K.;Zhao,R.;Smith,R.D.Proc.Natl.Acad.Sci.U.S.A.2002,
99, 11049–11054.
(10) Smith, R. D.; Anderson, G. A.; Lipton, M. S.; Pasa-Tolic, L.;
Shen,Y.;Conrads,T.P.;Veenstra,T.D.;Udseth,H.R.Proteomics2002,
2, 513–523.
(11) Zhu,W.;Smith,J.W.;Huang,C.M.J.Biomed.Biotechnol.2010,
2010, 840518.
(12) Hoﬀert, J. D.; Pisitkun, T.; Wang, G.; Shen, R. F.; Knepper,
M. A. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 7159–7164.
(13) Huber, A.; Bodenmiller, B.; Uotila, A.; Stahl, M.; Wanka, S.;
Gerrits, B.; Aebersold, R.; Loewith, R. Genes Dev. 2009, 23, 1929–1943.
(14) Niittyla,T.;Fuglsang,A.T.;Palmgren,M.G.;Frommer, W.B.;
Schulze, W. X. Mol. Cell Proteomics 2007, 6, 1711–1726.
(15) Stulemeijer, I. J.; Joosten, M. H.; Jensen, O. N. J. Proteome Res.
2009, 8, 1168–1182.
(16) Manes, N. P.; Dong, L.; Zhou, W.; Du, X.; Reghu, N.; Kool,
A. C.; Choi, D.; Bailey, C. L.; Petricoin, E. F., 3rd; Liotta, L. A.; Popov,
S. G. Mol. Cell Proteomics 2010, 10,1 –11.
(17) Gunaratne, R.; Braucht, D. W.; Rinschen, M. M.; Chou, C. L.;
Hoﬀert, J. D.; Pisitkun, T.; Knepper, M. A. Proc. Natl. Acad. Sci. U. S. A.
2010, 107, 15653–15658.
(18) Bodenmiller, B.; Wanka, S.; Kraft, C.; Urban, J.; Campbell, D.;
Pedrioli, P. G.; Gerrits, B.; Picotti, P.; Lam, H.; Vitek, O.; Brusniak,
M .Y . ;R o s c h i t z k i ,B . ;Z h a n g ,C . ;S h o k a t ,K .M . ;S c h l a p b a c h ,R . ;
Colman-Lerner, A.; Nolan, G. P.; Nesvizhskii, A. I.; Peter, M.; Loewith,
R.; Von Mering, C.; Aebersold, R. Sci. Signal 2010, 3,4 .
(19) Montoya, A.; Beltran, L.; Casado, P.; Rodriguez-Prados, J. C.;
Cutillas, P. R. Methods 2011, e-pub ahead of print.
(20) Bodenmiller, B.; Mueller, L. N.; Mueller, M.; Domon, B.;
Aebersold, R. Nat. Methods 2007, 4, 231–237.
(21) Li, Q. R.; Ning, Z. B.; Tang, J. S.; Nie, S.; Zeng, R. J. Proteome
Res. 2009, 8, 5375–5381.
(22) Simon, E. S.; Young, M.; Chan, A.; Bao, Z. Q.; Andrews, P. C.
Anal. Biochem. 2008, 377, 234–242.
(23) Choi, H.; Lee, H. S.; Park, Z. Y. Anal. Chem. 2008, 80,
3007–3015.
(24) Larsen, M. R.; Thingholm, T. E.; Jensen, O. N.; Roepstorﬀ, P.;
Jorgensen, T. J. Mol. Cell Proteomics 2005, 4, 873–886.
(25) Mazanek, M.; Mituloviae, G.; Herzog, F.; Stingl, C.; Hutchins,
J. R.; Peters, J. M.; Mechtler, K. Nat. Protoc. 2007, 2, 1059–1069.
(26) Thingholm,T.E.;Jorgensen, T. J.;Jensen,O. N.;Larsen, M.R.
Nat. Protoc. 2006, 1, 1929–1935.
(27) Jensen, S. S.; Larsen, M. R. Rapid Commun. Mass Spectrom.
2007, 21, 3635–3645.
(28) Premont,R.T.;Gainetdinov,R.R.Annu.Rev.Physiol.2007,69,
511–534.